Loading
Ceplene is a twice-daily injection of histamine given alongside low-dose interleukin-2 as maintenance treatment for adults with acute myeloid leukaemia in first remission, to help immune cells prevent relapse. It is authorised in Europe only.
Histamine dihydrochloride was authorised in the EU in October 2008 under exceptional circumstances, with low-dose interleukin-2, as maintenance therapy for adults with acute myeloid leukaemia in first complete remission, on a phase 3 trial of 320 patients in which the combination improved leukaemia-free survival compared with no maintenance; the label notes efficacy is not fully established over age 60 and an FDA application was not approvable in 2000. It is one of the very few approved maintenance immunotherapies in AML, though oral azacitidine (Onureg) and FLT3 inhibitors now fill that space, and it is little used. Flushing, headache, hypotension and injection-site reactions occur with each histamine dose.
Inhibits NADPH oxidase in monocytes and macrophages via H2 receptors, reducing the reactive oxygen species that inactivate NK and T cells and thereby protecting IL-2-activated lymphocytes in the leukaemic microenvironment.
1.Histamine dihydrochloride binds its target.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| EU | 2008 | Maintenance with interleukin-2 for adults with AML in first remission (exceptional circumstances) |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Histamine dihydrochloride" OR ABSTRACT:"Histamine dihydrochloride" OR TITLE:"Ceplene" OR ABSTRACT:"Ceplene") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Histamine dihydrochloride, not a curated reading list.
Shares Cytokines & engineered cytokines, Acute myeloid leukaemia.
Shares Aldesleukin (high-dose IL-2), Cytokines & engineered cytokines.
Shares Aldesleukin (high-dose IL-2), Cytokines & engineered cytokines.
Shares Cytokines & engineered cytokines, Acute myeloid leukaemia.
Shares Aldesleukin (high-dose IL-2), Cytokines & engineered cytokines.
Shares Cytokines & engineered cytokines, Acute myeloid leukaemia.